Adam M. Veness's most recent trade in Dianthus Therapeutics Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Dianthus Therapeutics Inc | Adam M. Veness | SVP, General Counsel and Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Adam M. Veness | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 96,100 | 96,100 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Adam M. Veness | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 177,000 | 177,000 | - | - | Stock Option (Right to buy) |